Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Shuichi, Tatarano"'
Autor:
Wataru Fukumoto, Shunsuke Okamura, Motoki Tamai, Junya Arima, Ichiro Kawahara, Ikumi Fukuda, Akihiko Mitsuke, Takashi Sakaguchi, Satoshi Sugita, Ryosuke Matsushita, Shuichi Tatarano, Yasutoshi Yamada, Masayuki Nakagawa, Hideki Enokida, Hirofumi Yoshino
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Chemotherapy including cisplatin is recommended for the treatment of advanced bladder cancer, but its effectiveness is limited due to the acquisition of drug resistance. Although several mechanisms of cisplatin resistance have bee
Externí odkaz:
https://doaj.org/article/7d46651dce6b448899636a311a74c173
Autor:
Ichiro Kawahara, Hirofumi Yoshino, Wataru Fukumoto, Junya Arima, Saeki Saito, Gang Li, Ikumi Fukuda, Akihiko Mitsuke, Takashi Sakaguchi, Satoru Inoguchi, Ryosuke Matsushita, Masayuki Nakagawa, Shuichi Tatarano, Yasutoshi Yamada, Hideki Enokida
Publikováno v:
Molecular Oncology, Vol 18, Iss 9, Pp 2196-2211 (2024)
Gemcitabine plus cisplatin (GC) combination chemotherapy is the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, most cases develop resistance to this therapy. We investigated whether drug resistanc
Externí odkaz:
https://doaj.org/article/c2d8257116da49f8983df134c431822c
Autor:
Masaki Shiota, Shota Nemoto, Ryo Ikegami, Shuichi Tatarano, Toshiyuki Kamoto, Keita Kobayashi, Hideki Sakai, Tsukasa Igawa, Tomomi Kamba, Naohiro Fujimoto, Akira Yokomizo, Seiji Naito, Masatoshi Eto
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024)
Abstract Background The predictive power of the treatment efficacy and prognosis in primary androgen deprivation therapy (ADT) for advanced prostate cancer is not satisfactory. The objective of this study was to integrate genetic and clinical data to
Externí odkaz:
https://doaj.org/article/db4199766c0a496080e9b53340cb9acc
Autor:
Shinichi Sakamoto, Kodai Sato, Takahiro Kimura, Yoshiyuki Matsui, Yusuke Shiraishi, Kohei Hashimoto, Hideaki Miyake, Shintaro Narita, Jun Miki, Ryuji Matsumoto, Takuma Kato, Toshihiro Saito, Ryotaro Tomida, Masaki Shiota, Akira Joraku, Naoki Terada, Shigetaka Suekane, Tomoyuki Kaneko, Shuichi Tatarano, Yuko Yoshio, Takayuki Yoshino, Naotaka Nishiyama, Eiryo Kawakami, Tomohiko Ichikawa, Hiroshi Kitamura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract A multicenter study of nonmetastatic castration-resistant prostate cancer (nmCRPC) was conducted to identify the optimal cut-off value of prostate-specific antigen (PSA) doubling time (PSADT) that correlated with the prognosis in Japanese nm
Externí odkaz:
https://doaj.org/article/916b6526270845538ce6a993714a45e5
Autor:
Takashi Sakaguchi, Akihiko Mitsuke, Yoichi Osako, Yasutoshi Yamada, Himawari Takeyama, Risako Ogawa, Katsuya Takahashi, Yukiko Hirohata, Sayuri Yamamoto, Junya Arima, Wataru Fukumoto, Satoshi Sugita, Satoru Inoguchi, Ryosuke Matsushita, Hirofumi Yoshino, Shuichi Tatarano, Hideki Enokida
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-12 (2024)
Abstract Background Kidney transplant recipients (KTRs) are at risk of severe coronavirus disease 2019 (COVID-19), and even now that Omicron subvariants have become dominant, cases of severe disease are certain to occur. The aims of this retrospectiv
Externí odkaz:
https://doaj.org/article/1a625451670442f995b20a2abfce3ae8
Autor:
Hirofumi Yoshino, Seiya Yokoyama, Motoki Tamai, Shunsuke Okamura, Sayaka Iizasa, Takashi Sakaguchi, Yoichi Osako, Satoru Inoguchi, Ryosuke Matsushita, Yasutoshi Yamada, Masayuki Nakagawa, Shuichi Tatarano, Akihide Tanimoto, Hideki Enokida
Publikováno v:
FEBS Open Bio, Vol 13, Iss 6, Pp 1056-1066 (2023)
Combination chemotherapy with gemcitabine and cisplatin (GC) is recommended as the primary treatment for advanced bladder cancer (BC). However, the benefits of this approach are limited owing to the acquisition of drug resistance. Here, we found that
Externí odkaz:
https://doaj.org/article/720e8450134c49778a8939c7650a0022
Autor:
Hirofumi Yoshino, Akihiko Mitsuke, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Satoru Inoguchi, Shuichi Tatarano, Yasutoshi Yamada, Hideki Enokida
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 11, Iss , Pp 100260- (2023)
Treatment of advanced renal cell carcinoma (RCC) typically involves surgery, even in challenging cases (ie, inferior vena cava [IVC] tumor thrombus, stage 3b [T3b] disease). Although tyrosine kinase inhibitor (TKI)-based neoadjuvant therapy shrinks p
Externí odkaz:
https://doaj.org/article/be44dd34b8b7459da0e616613ada2405
Autor:
Motoki Tamai, Shuichi Tatarano, Shunsuke Okamura, Wataru Fukumoto, Issei Kawakami, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Masaya Yonemori, Yasutoshi Yamada, Masayuki Nakagawa, Hideki Enokida, Hirofumi Yoshino
Publikováno v:
Molecular Oncology, Vol 16, Iss 6, Pp 1329-1346 (2022)
Patients with advanced bladder cancer are generally treated with a combination of chemotherapeutics, including gemcitabine, but the effect is limited due to acquisition of drug resistance. Thus, in this study, we investigated the mechanism of gemcita
Externí odkaz:
https://doaj.org/article/c55b1c48d9a940969d81190a0f2acebb
Autor:
Akihiko Mitsuke, Takahiko Ohbo, Junya Arima, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Hirofumi Yoshino, Shuichi Tatarano, Yasutoshi Yamada, Hajime Sasaki, Tatsu Tanabe, Nobuyuki Fukuzawa, Hiroshi Tanaka, Yoshihiko Nishio, Enokida Hideki, Hiroshi Harada
Publikováno v:
PLoS ONE, Vol 18, Iss 10, p e0287059 (2023)
The development of diabetes mellitus (DM) after living donor kidney transplantation (KT) is a risk factor for worsening transplant kidney function, cardiac disease, and cerebrovascular disease, which may affect prognosis after KT. At our institution,
Externí odkaz:
https://doaj.org/article/0f18739c3b714f4bb6465e0e6bd7a607
Autor:
Katsuhiro Ito, Takashi Kobayashi, Takahiro Kojima, Kensuke Hikami, Takeshi Yamada, Kosuke Ogawa, Kenji Nakamura, Naoto Sassa, Akira Yokomizo, Takashige Abe, Kazunari Tsuchihashi, Shuichi Tatarano, Junichi Inokuchi, Ryotaro Tomida, Maki Fujiwara, Atsushi Takahashi, Kazumasa Matsumoto, Kosuke Shimizu, Hiromasa Araki, Ryoma Kurahashi, Yu Osaki, Yu Tashiro, Masayuki Uegaki, Osamu Ogawa, Hiroshi Kitamura, Hiroyuki Nishiyama
Publikováno v:
Cancer Medicine, Vol 10, Iss 10, Pp 3188-3196 (2021)
Abstract Background The benefits of pembrolizumab in patients with advanced urothelial carcinoma (UC) and impaired performance status (PS) remain unknown. This study assessed the safety and efficacy of pembrolizumab in patients with platinum‐refrac
Externí odkaz:
https://doaj.org/article/98ad661f861345338f17b09eccbd721b